NCT03300557View on ClinicalTrials.gov

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 15, 2017

Primary Completion Date

December 13, 2023

Study Completion Date

August 14, 2025

Conditions

Atypical HyperplasiaEndometrial Atypical Hyperplasia/Endometrioid Intraepithelial NeoplasiaEndometrial CarcinomaFIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid Adenocarcinoma

Interventions

DRUG

Exemestane

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacokinetic Study

Correlative studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (3)

35233

University of Alabama at Birmingham Cancer Center, Birmingham

53792

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT03300557 - Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer | Biotech Hunter | Biotech Hunter